Previous 10 | Next 10 |
NRx Pharmaceuticals, Inc. (NRXP) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Suzanne Messere - Investor Relations Stephen Willard - Chief Executive Officer Seth Van Voorhees - Chief Financial Officer and Treasurer Jonath...
NRx Pharmaceuticals press release ( NASDAQ: NRXP ): Q3 GAAP EPS of -$0.14. As of September 30, 2022, cash was $18.2M compared to $27.6M as of December 31, 2021. The company believes that it has sufficient funds to support our ongoing clinical development plans for at l...
NRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update PR Newswire Completed a technology transfer, submitted a new manufacturing file to the United States ("U.S.") Food and Drug Administration ("FDA"), and released new drug p...
Relief Therapeutics ( OTCQB:RLFTF ) ( OTCQB:RLFTD ) and NRx Pharmaceuticals ( NASDAQ: NRXP ) said they signed settlement agreements to resolve their pending litigation related to experimental COVID-19 therapy Zyesami (aviptadil). As part of the settlement, N...
Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements PR Newswire Ad hoc announcement pursuant to Art. 53 LR GENEVA and RADNOR, Pa. , Nov. 14, 2022 /PRNewswire/ -- RELIEF THERAPEU...
Penny Stocks To Buy According To 5 Wall Street Analysts Contrary to popular opinion, penny stocks aren’t just lottery tickets or no-name companies. This year, more than others, this has become a fact, especially considering the massive sell-off in the broader markets. Househo...
NRx Pharmaceuticals to Report Third Quarter 2022 Results on November 14, 2022 PR Newswire --Company to Host Conference Call November 14, 2022 , at 8:00AM ET --- RADNOR, Pa. , Nov. 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Na...
NRx Pharmaceuticals ( NASDAQ: NRXP ) announced Wednesday the release of the first commercially produced batch of NRX-101, an investigational therapy set to undergo a Phase 3 trial for suicidal bipolar depression in the near term. The company shares added ~11% pre-market in...
NRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process PR Newswire Manufacturing files submitted to U.S. Food and Drug Administration The company has now completed its transition to U.S.-based manufacturing NRX-101 is now ma...
NRx Pharmaceuticals Closes $11 Million Unsecured Debt Financing PR Newswire RADNOR, Pa. , Nov. 7, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage CNS biopharmaceutical company, today...
News, Short Squeeze, Breakout and More Instantly...
NRX Pharmaceuticals Inc. Company Name:
NRXP Stock Symbol:
NASDAQ Market:
NRX Pharmaceuticals Inc. Website:
NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing PR Newswire New Drug Application (NDA) for Accelerated Approval planned for NRX-101 in people with bipolar depression and akathisia in 202...
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024 PR Newswire RADNOR, Pa. , June 20, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"...
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors PR Newswire Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology ...